A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease - Full Text View

Sponsors and Collaborators:	Pfizer Alzheimer's Disease Cooperative Study (ADCS)
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00566397

Purpose

This Phase 2 study is designed to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.

Condition	Intervention	Phase
Alzheimer's Disease	Drug: PF-04494700 Drug: Placebo	Phase II

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:	A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease

Further study details as provided by Pfizer:

Primary Outcome Measures:

Evaluate the efficacy of PF 04494700 relative to placebo. Change from baseline in a standardized cognitive measure after 18 months of treatment. [ Time Frame: 18 Month ] [ Designated as safety issue: No ]
Examine the safety and tolerability of PF 04494700 relative to placebo. Adverse events, vital signs, physical exam, neuro exam, 12-lead ECG, lab tests (hematology, blood chemistry, urinalysis) and brain magnetic resonance imaging (MRI). [ Time Frame: 18 Month ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Evaluate the effects of PF 04494700 on potential biomarkers of RAGE inhibition [ Time Frame: 18 Month ] [ Designated as safety issue: No ]
Evaluate the potential dose response of PF 04494700 [ Time Frame: 18 Month ] [ Designated as safety issue: No ]
Evaluate the pharmacokinetics and characterize the pharmacokinetic (PK)/ pharmacodynamic (PD) relationship of PF 04494700 to potential biomarkers and relevant efficacy and safety endpoints [ Time Frame: 18 Month ] [ Designated as safety issue: No ]

Estimated Enrollment:	400
Study Start Date:	December 2007
Estimated Study Completion Date:	March 2011
Estimated Primary Completion Date:	March 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: PF-04494700 15 mg for 6 days followed by daily dosing of 5mg
2: Experimental	Drug: PF-04494700 60 mg for 6 days followed by daily dosing of 20mg
3: Placebo Comparator	Drug: Placebo Placebo

Eligibility

Criteria

Inclusion Criteria:

Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening.
Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization

Exclusion Criteria:

Current evidence or history of neurological, psychiatric and any other illness that could contribute to non-Alzheimer's dementia.
Known history of familial AD or any evidence for early onset AD known or possibly associated with genetic mutations.
Evidence or history of diabetes mellitus Type 1 or Type 2.
History or symptoms of autoimmune disorders.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00566397

Contacts

Contact: Alzheimer's Disease Education and Referral Center (ADEAR)	1-800-438-4380
Contact: Pfizer CT.gov Call Center	1-800-718-1021

Sponsors and Collaborators

Pfizer

Alzheimer's Disease Cooperative Study (ADCS)

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Responsible Party:	Pfizer, Inc. ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:	B0341002
Study First Received:	November 29, 2007
Last Updated:	December 18, 2008
ClinicalTrials.gov Identifier:	NCT00566397
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

RI, RI Study, Rage Inhibitors

Study placed in the following topic categories:

Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Alzheimer Disease
Central Nervous System Diseases
Neurodegenerative Diseases

Brain Diseases
Dementia
Cognition Disorders
Delirium

Additional relevant MeSH terms:

Nervous System Diseases
Tauopathies

ClinicalTrials.gov processed this record on January 16, 2009